Maximilian Diehn, M.D., Ph.D.

Back to Profile

Publication Details

  • Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.

    Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, Quon A, Le QT, Diehn M, Loo BW. Lung Cancer. 2012; 78 (3): 219-24

    To test whether (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) imaging metrics correlate with outcomes in patients with stage I non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy (SABR).

    PubMedID: 23009727

Stanford Medicine Resources:

Footer Links: